Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX464 in Moderate to Severe Active Crohn's Disease
NCT03905109Phase 3Withdrawn
- Sponsor
- Abivax
- Start
- Sep 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of obefazimod in Crohn's disease (4 cohorts), sponsored by Abivax. Primary endpoints: Induction of Clinical Remission at 12 weeks and Induction of Endoscopic Improvement at 12 weeks. Planned start Sep 2022; status: withdrawn.
02
Drugs
obefazimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03905109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03905109.